Look back at pharma news in week to September 14

16 September 2018

By Barbara Obstoj-Cardwell. Editor

As US Food and Drug Administration rejects approval of GlaxoSmithKline's Nucala for COPD, the company has been touting new data for the drug in asthma. Also on the US regulatory front, the FDA Breakthrough designation of AstraZeneca’s tezepelumab is seen as important for the drugmaker’s asthma ambitions, while in Europe, Merck & Co gained approval of Keytruda in the first-line cancer setting. Elsewhere, Gilead Sciences and Galapagos released positive results with filgotinib, a rheumatoid arthritis drug recently rejected by AbbVie, and Boehringer Ingelheim took up the option to acquire ViraTherapeutics.

COPD rejection means GSK can’t breathe easy on Nucala

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK